Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 4/20 | 0.65 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.65 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.56 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.56 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.56 |
| ▸ | RET | P07949 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17776133 | 1.00 | PRCP (0.65) | PRCPSLC22A1ADRB2ADRB1ADRB3 | |
| SCHEMBL31482774 | 1.00 | PRCP (0.65) | PRCPSLC22A1ADRB2ADRB1ADRB3 | |
| Hydrochloric Acid SCHEMBL31397779 | 0.98 | PRCP (0.63) | PRCPSLC22A1ADRB2ADRB1ADRB3 | |
| Hydrochloric Acid SCHEMBL31482772 | 0.98 | PRCP (0.63) | PRCPSLC22A1ADRB2ADRB1ADRB3 | |
| Bromide SCHEMBL31482773 | 0.98 | PRCP (0.63) | PRCPSLC22A1ADRB2ADRB1ADRB3 | |
| Oxalic Acid SCHEMBL31482775 | 0.91 | OPRM1 (0.59) | PRCPSLC22A1ADRB2ADRB1ADRB3 | |
| Maleic Acid SCHEMBL31563607 | 0.87 | OPRM1 (0.55) | PRCPSLC22A1ADRB2ADRB1ADRB3 | |
| SCHEMBL13977536 | 0.83 | PRCP (0.67) | PRCPSLC22A1OPRM1GAAALDH1A1 | |
| SCHEMBL16455043 | 0.81 | PRCP (0.68) | PRCPSLC22A1OPRM1GAAALDH1A1 | |
| SCHEMBL10434781 | 0.81 | PRCP (0.65) | PRCPSLC22A1OPRM1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220395496-A1 | PIPERIDINYL AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2022-12-15 | — | — | US | claimed |
| CN-114401954-A | Piperidinylamine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2022-04-26 | — | — | CN | claimed |
| CN-1072679-C | Aza steroid preparation and its use | UNIV CHONGQING MEDICAL (CN) | 2001-10-10 | — | — | CN | claimed |
| CN-1124251-A | Aza steroid preparation and its use | UNIV CHONGQING MEDICAL (CN) | 1996-06-12 | — | — | CN | claimed |
| WO-1993002707-A1 | NEW ANTI-DIARRHEIC AGENTS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1993-02-18 | — | — | WO | claimed |
| JP-5239030-A | — | — | None | — | — | JP | disclosed |
| US-20220395496-A1 | PIPERIDINYL AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2022-12-15 | — | — | US | disclosed |
| CN-114401954-A | Piperidinylamine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-111171027-B | Preparation method of (R) -praziquantel | 浙江工业大学 | 2021-07-30 | — | — | CN | disclosed |
| WO-2021052892-A1 | PIPERIDINYL AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2021-03-25 | — | — | WO | disclosed |
| CN-111171027-A | Preparation method of (R) -praziquantel | 浙江工业大学 | 2020-05-19 | — | — | CN | disclosed |
| US-10597378-B2 | Tetrahydroisoquinolines for use as MOR/NOP dual agonists | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2020-03-24 | — | — | US | disclosed |
| WO-1996000730-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-01-11 | — | — | WO | disclosed |
| JP-H05239030-A | AMINOMETHYLTETRAHYDROISOQUINOLINE DERIVATIVE AND ITS PRODUCTION | ASAHI BREWERIES LTD | 1993-09-17 | — | — | JP | disclosed |
| US-4497952-A | Process for the production of (±)-4-oxo-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinoline derivatives | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 1985-02-05 | — | — | US | disclosed |
| US-4362875-A | Process for preparing (1-acylaminomethyl)-1,2,3,4-tetrahydroisoquinolines | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1982-12-07 | — | — | US | disclosed |
| US-4362875-A | Process for preparing (1-acylaminomethyl)-1,2,3,4-tetrahydroisoquinolines | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1982-12-07 | — | — | US | disclosed |
| US-4162319-A | ANTHELMINTICS, PSYCHOTROPIC, CNS, HYPOGLYCOMIC AGENTS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1979-07-24 | — | — | US | disclosed |
| US-4120961-A | ANTIHELMINTICS, CNS ACITVITY | E. MERCK (DE) | 1978-10-17 | — | — | US | disclosed |
| US-4051243-A | RING SUBSTITUTED PYRAZINO-ISOQUINOLINE DERIVATIVES AND THEIR PREPARATION | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1977-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10597378-B2 | Tetrahydroisoquinolines for use as MOR/NOP dual agonists | OPRL1, OPRM1, OPRK1 | PRCP 2247/4885SLC22A1 2574/4885ADRB2 132/4885 |
| US-20220395496-A1 | PIPERIDINYL AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | ARG1, PRMT1, HRH3 | PRCP 2196/4885SLC22A1 1242/4885ADRB2 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.